Elafibranor - CAS 923978-27-2
Catalog number: B0084-074234
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H24O4S
Molecular Weight:
384.49
COA:
Inquire
Targets:
PPAR
Description:
Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and total cholesterol in the liver of ApoE2-KI wild-type mice. Elafibranor is identified as a drug candidate for the treatment of cardiometabolic diseases such as diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-074234 250 mg $299 In stock
Bulk Inquiry
Brife Description:
PPARα/δ agonist
Appearance:
Yellow Solid
Synonyms:
GFT-505; GFT505; 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid
MSDS:
Inquire
Application:
potential treatment of cardiometabolic diseases
Melting Point:
140-144°C
InChIKey:
AFLFKFHDSCQHOL-IZZDOVSWSA-N
InChI:
InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
Canonical SMILES:
CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)C=CC(=O)C2=CC=C(C=C2)SC
1.Emerging drugs for hyperlipidemia.
Paras C;Hussain MM;Rosenson RS Expert Opin Emerg Drugs. 2010 Sep;15(3):433-51. doi: 10.1517/14728214.2010.481282.
IMPORTANCE OF THE FIELD: ;Elevated concentrations of low-density lipoprotein (LDL) cholesterol are associated with increased risk of coronary atherosclerosis, and morbidity and mortality from coronary heart disease (CHD). Lowering of LDL cholesterol leads to a reduction in cardiovascular morbidity and all-cause mortality in individuals at risk for cardiovascular events and patients with established CHD. The mainstays of lipid lowering therapy today are the HMG-CoA reductase inhibitors (statins); however, the residual risk of cardiovascular events amongst individuals treated with statins remains a major healthcare concern.;AREAS COVERED IN THIS REVIEW: ;Emerging targets for lipid lowering therapy target pathways that regulate lipoprotein assembly, lipoprotein clearance and pro-atherogenic lipoprotein modification. These emerging drugs have novel mechanisms that include inhibition of lipoprotein assembly (antisense mRNA inhibitors of apolipoprotein B and microsomal transfer protein inhibitors), enhanced lipoprotein clearance (proprotein convertase subtilisin kexin type 9, thyroid hormone analogues), inhibition of pro-atherogenic lipoprotein remodeling (cholesterol ester transfer protein inhibitors (dalcetrapib, anacetrapib) and peroxisome proliferator activator agents (GFT-505, aleglitazar)) and inhibition of lipoprotein modification (heme oxygenase-1 inhibitor (succinobucol), phospholipase A(2) inhibitors (varespladib, darapladib)).
2.Novel Pharmacotherapy Options for NASH.
Ratziu V Dig Dis Sci. 2016 May;61(5):1398-405. doi: 10.1007/s10620-016-4128-z. Epub 2016 Mar 22.
While simple to recommend, diet and lifestyle measures as a first-line therapy for nonalcoholic steatohepatitis (NASH) are hardly a model of successful therapy, as most clinicians can testify. They can be complex to implement, hard to sustain, and of limited efficacy in advanced stages of the disease. The need for specific pharmacotherapy is now acknowledged by practitioners, the pharmaceutical industry, and regulators and is largely expected by patients. The result is a clear move away from products developed second hand for NASH (such as pioglitazone or metformin) or from generic, non-specific hepatoprotectors (such as pentoxifylline, ursodeoxycholic acid, or antioxidants) toward molecules developed and tested specifically for NASH that aim to correct one or several of the pathways of liver injury in this disease. The two most advanced molecules, obeticholic acid and elafibranor, have shown encouraging data on improving hepatic histology. Both compounds appear to clear NASH, with obeticholic acid improving liver fibrosis and elafibranor improving the glycemic and lipid profile. Much larger trials, currently ongoing, will need to confirm these preliminary data and better characterize the safety and tolerability profile.
3.GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Cariou B;Staels B Expert Opin Investig Drugs. 2014 Oct;23(10):1441-8. doi: 10.1517/13543784.2014.954034. Epub 2014 Aug 28.
INTRODUCTION: ;PPARs are nuclear receptors that play key roles in the regulation of metabolism and inflammation. GFT505 is a new dual agonist of the PPARα and PPARδ isoforms, which improves lipid and glucose metabolism in type 2 diabetes mellitus (T2DM) and exerts hepatoprotective effects in mouse models of nonalcoholic fatty liver disease (NAFLD).;AREAS COVERED: ;This evaluation focuses on the pharmacology and clinical activity of GFT505 in metabolic diseases, including T2DM, dyslipidemia and NAFLD, as well as its promise as a therapeutic option for the treatment of nonalcoholic steatohepatitis. Original publications in English were selected, as well as abstracts of presentations in international congresses. Ongoing clinical trials were identified using the Clinicaltrial.gov database.;EXPERT OPINION: ;Results from the completed short-term (4 - 8 weeks) Phase IIa studies indicate that GFT505 decreases plasma triglyceride levels and increases high-density lipoprotein-cholesterol, while lowering low-density lipoprotein-cholesterol in prediabetic patients. Hyperinsulinemic-euglycemic clamp studies have also demonstrated an insulin-sensitizing effect of GFT505, with a strong effect on the liver, with a significant lowering effect on plasma liver enzymes.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PPAR Products


CAS 1065756-01-5 Parstatin (mouse)

Parstatin (mouse)
(CAS: 1065756-01-5)

Parstatin, a 41-mer peptide which is cleaved upon activation of Proteinase-Activated Receptor 1, attenuates endothelial cell migration and proliferation (IC50 ~...

CAS 810677-36-2 PPARα-MO-1

PPARα-MO-1
(CAS: 810677-36-2)

A potent PPARα modulator

CAS 702680-17-9 CP 775146

CP 775146
(CAS: 702680-17-9)

CP 775146 is a high affinity PPARα agonist and show hypolipidemic activity in vivo.

CAS 331741-94-7 Muraglitazar

Muraglitazar
(CAS: 331741-94-7)

Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).

FH535 sodium salt

FH535 sodium salt is a dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of th...

CAS 927961-18-0 Lanifibranor

Lanifibranor
(CAS: 927961-18-0)

Lanifibranor is a peroxisome proliferator-activated receptors (PPAR) agonist.

GSK7227
(CAS: 1067214-81-6)

GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells.

CAS 161600-01-7 MCC-555

MCC-555
(CAS: 161600-01-7)

MCC-555, a thiazolidinedion derivative, has been found to be a PPAR agonist that was once studied as hyperglycaemic and hyperlipidaemic. The Phase II trial agai...

CAS 1393371-39-5 MHY 908

MHY 908
(CAS: 1393371-39-5)

MHY 908 is a dual PPARα/γ agonist and a melanogenesis inhibitor that suppresses mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 exhibits more potent a...

CAS 196808-24-9 GW1929

GW1929
(CAS: 196808-24-9)

A potent, tyrosine-based peroxisome proliferator-activated receptor γ (PPARγ) agonist (EC50 = 13 nM for murine receptor and 6.2 nM for human receptor in cell-ba...

CAS 49562-28-9 Fenofibrate

Fenofibrate
(CAS: 49562-28-9)

Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.It is used alone or along with statins in the treatment of hypercho...

CAS 1014691-61-2 GSK0660

GSK0660
(CAS: 1014691-61-2)

GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...

CAS 25812-30-0 Gemfibrozil

Gemfibrozil
(CAS: 25812-30-0)

Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the b...

CAS 223132-37-4 Inolitazone

Inolitazone
(CAS: 223132-37-4)

Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...

CAS 111-58-0 Oleylethanolamide

Oleylethanolamide
(CAS: 111-58-0)

Oleylethanolamide is an endogenous agonist for PPARα with an EC50 value of 120 nM in a transactivation assay. Oleylethanolamide is also a selective GPR55 agonis...

CAS 425671-29-0 LY-518674

LY-518674
(CAS: 425671-29-0)

LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +...

CAS 1639792-20-3 Saroglitazar (Magnesium)

Saroglitazar (Magnesium)
(CAS: 1639792-20-3)

Saroglitazar magnesium is a dual PPAR agonist with potent predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, res...

CDDO Imidazolide
(CAS: 443104-02-7)

CDDO Imidozolide is a synthetic triterpenoid as Nrf2 signaling activator with highly active in suppressing cellular proliferation of human leukemia and breast c...

CAS 317318-70-0 GW501516

GW501516
(CAS: 317318-70-0)

GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.

CAS 923978-27-2 Elafibranor

Elafibranor
(CAS: 923978-27-2)

Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and tot...

Chemical Structure

CAS 923978-27-2 Elafibranor

Quick Inquiry

Verification code

Featured Items